Hematology prior authorization at UPMC Health Plan
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
UPMC Health Plan hematology PA at a glance
UPMC Health Plan reviews hematology PA submissions against its medical policy library, with rules drawn primarily from NCCN + ASH (American Society of Hematology). UPMC Health Plan-specific context: Integrated payer-provider arm of UPMC (~4M members). Western PA dominant. The Highmark-UPMC consent decree (expired June 2019) governed cross-network access historically; subsequent commercial agreements maintain some access. PA Insurance Department oversight.
Documentation packet — what to send
- Diagnosis with ICD-10 (CLL, MM, NHL, etc.)
- Stage / risk stratification
- Molecular markers (BCR-ABL, TP53, IGHV, FISH)
- Prior lines of therapy with response
- Performance status
Common denial patterns to pre-empt
Patterns observed in hematology across payers, and where UPMC Health Plan's book of business overlaps:
- Off-label use (e.g., rituximab for non-Hodgkin's vs autoimmune)
- Indication-specific dosing
- Genetic testing (BCR-ABL, BRAF, TP53) not documented
- Step therapy in CLL / lymphoma
- Site of service for infusion
Appeal angles when UPMC Health Plan denies
- NCCN Compendium citation for hematologic malignancy
- Molecular / cytogenetic test results supporting indication
- Performance status documentation
- Documented response/failure of prior lines
Peer-to-peer prep
- Bring the molecular pathology report
- Quote NCCN Compendium category (1, 2A, 2B)
- Reference the pivotal trial for the prescribed regimen
- Document prior-line response (CR, PR, SD, PD) explicitly
Drug-specific PA criteria at UPMC Health Plan
Deep dives on each drug's PA criteria at UPMC Health Plan:
Frequently asked questions
What documentation does UPMC Health Plan need for hematology prior authorizations?
UPMC Health Plan's PA packet for hematology typically includes: Diagnosis with ICD-10 (CLL, MM, NHL, etc.); Stage / risk stratification; Molecular markers (BCR-ABL, TP53, IGHV, FISH); Prior lines of therapy with response. NCCN + ASH (American Society of Hematology) citations strengthen the submission.
What's the turnaround at UPMC Health Plan?
UPMC Health Plan standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which hematology drugs does UPMC Health Plan most often PA-restrict?
Top targets in hematology: rituximab, imatinib, ibrutinib, lenalidomide, apixaban. Each follows the per-drug step therapy + documentation requirements published in UPMC Health Plan's medical policy library.
How do I prep a peer-to-peer with UPMC Health Plan in hematology?
Bring the molecular pathology report Quote NCCN Compendium category (1, 2A, 2B) Have the policy URL and the patient's chart open before the call.
Generate a Hematology PA packet
Open ApprovalHelp — generate a hematology PA packet tailored to UPMC Health Plan's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com